CAR T cell therapy for lymphomas

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "CAR T cell therapy for lymphomas"

Transcription

1 CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX

2 CAR T cell therapy What are CAR T cells? Do they work for lymphomas? How do they work and what are the side effects? What is the future?

3 Chimeric Antigen Receptor (CAR) Modified T cells Normal T cell CAR T cell Genetically engineered T cells altered to express an artificial receptor, CAR CD19 Adapted from Hinrichs & Restifo. Nat Biotech 2013

4 Development of CAR T cell therapy Cytotoxicity Proliferation + ++ Cytokine secretion + ++ In vivo persistence + ++ Adapted from Maus et al. Blood 2014;123:

5 2 nd generation CD19 CAR T cells in clinic MSKCC/Fred Hutch NCI U Penn MDACC CD19 Ab CD28/4-1BB CD3z Gene transfer Retrovirus Retrovirus Lentivirus Sleeping beauty Juno Therapeutics Kite Pharma Novartis Ziopharm

6 CAR T cell therapy What are CAR T cells? Do they work for lymphomas? How do they work and what are the side effects? What is the future?

7 General Treatment Schema 2-4 wks manufacturing Apheresis / Blood draw Days -5 to -3 Day 0 Conditioning chemotherapy Cyclophosphamide Fludarabine CAR T cells ( million cells)

8 NCI Study CD19 CAR in refractory B-cell lymphomas - CD19/CD3z/CD28 Lymphoma subtype n ORR CR PR DLBCL/PMBCL 17 65% 35% 30% CLL 7 86% 57% 29% Indolent NHL 5 100% 25% 75% Total 29 76% 38% 38% 16 patients still in response; 12 ongoing > 1 year None of the CRs have relapsed 3 patients were re-treated after progression and all 3 responded Kochenderfer, et al, J Clin Oncol, 2014 Kochenderfer, et al, ASH, 2014 Bot et al, ASCO, 2015

9 U Penn Study CD19 CAR in relapsed or refractory B-cell lymphomas - CD19/CD3z/4-1BB Lymphoma subtype n ORR CR PR DLBCL 15 47% 40% 7% FL 11 73% 64% 9% MCL 2 50% 50% - Total 28 57% 51% 6% None of the CRs have relapsed Schuster et al, ASH 2015, Abstract # 183

10 FHCRC Study CD19 CAR in relapsed or refractory B-cell lymphomas CD19/CD3z/CD28 Lymphoma subtype n ORR CR PR DLBCL/tNHL 18 50% 22% 28% FL 6 67% 33% 33% MCL 4 25% - 25% CLL 6 67% 50% 17% Total 34 52% 26% 26% CAR T cells reach higher peaks and persist longer with Cy/Flu conditioning regimen compared with Cy regimen Turtle et al, ASH 2015, Abstract # 184

11 Resolution of liver and spleen masses PMBCL DLBCL Kochenderfer, et al, J Clin Oncol, 2014

12 CAR T cell therapy What are CAR T cells? Does it work for lymphomas? How do they work and what are the side effects? What is the future?

13 CAR T cell response to antigen CAR T cell CD19 Proliferate Make cytokines Kill the target cells

14 CAR T-cell expansion after infusion Peak day 7-17 Kochenderfer, et al, J Clin Oncol, 2014

15 Summary of Toxicities Cytokine release syndrome (CRS) Fever, hypotension, hypoxia Generally resolves within 1-3 weeks Managed using IL-6 receptor blockade (tocilizumab) Neurotoxicity (reversible) aphasia/dysphasia, confusion, somnolence, tremors, seizures Low blood counts and infection (from conditioning chemo) Tumor lysis syndrome (manageable) Hypogammaglobulinemia and infections -- Late toxicity due to B-cell depletion

16 CAR T cell therapy What are CAR T cells? Does it work for lymphomas? How does it work and what are the side effects? What is the future? Can the CAR T cells be centrally manufactured and shipped to treatment facilities? Can it be made into an off-the shelf product? Will it be effective for other lymphomas? How can the efficacy be improved? How can the toxicity be lowered?

17 Other targets for CAR T cell therapy Lymphoma subtype Targets Phase of development B-cell lymphomas and leukemias (DLBCL, BL, FL, MCL, MZL, CLL, ALL) CD19, CD22 Phase II/Registration Hodgkin lymphoma CD30 Preclinical / Phase I T-cell lymphomas CD5, CD30 Preclinical / Phase I Multiple myeloma CD19, BCMA, CS1/SLAMF7 Preclinical / Phase I AML CD123 Preclinical

18 Other CAR T Cell Trials Target Institution / Sponsor N Histology Disease setting Efficacy Ref CD30 Baylor 9 HL ALCL Relapsed/ Refractory 1CR 1PR 4SD ASH 2015, Abst 185 BCMA NCI 11 MM Relapsed / Refractory 1CR 3 PR ASH 2015, Abst LBA-1 CD19 Cellectis (Off-the shelf) 1 ALL Refractory CR ASH 2015, Abst 2046

19 Summary Highly effective in patients with MRD or bulky disease in aggressive (DLBCL, PMBCL, DHL, THL, Burkitt s) and indolent B-NHL, CLL, ALL, HL, and MM Appears to be safe in refractory patients as well as after autologous- or allogeneic-sct Cytokine release syndrome (CRS) and neurotoxicity are the major toxicities but are reversible Efficacy and toxicity appear to be comparable between the various 2 nd generation CAR T cell products Multicenter phase 2 registration trials are ongoing in lymphomas Off-the shelf allogeneic CAR T cells are entering clinical trials Combination strategies are being tested in preclinical studies

20 Acknowledgements Patients Physicians Scientists Nurses Clinical research staff Laboratory research staff Funding agencies Sponsors Kite Pharma Novartis Juno Therapeutics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor T Cell Therapy Chimeric Antigen Receptor T Cell Therapy Yi Lin, MD, PhD Mayo Clinic, Rochester, MN Alliance Spring Group Meeting - May 13, 2016 Presentation Objectives l Scientific overview of chimeric antigen receptor

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

Lymphoma Diagnostic Work-up from a Lab Perspective

Lymphoma Diagnostic Work-up from a Lab Perspective Lymphoma Diagnostic Work-up from a Lab Perspective Mohamed E. Salama M.D. Mohamed.salama@path.utah.edu Lymphoproliferative Disorders Malignant lymphoma 1. Non-Hodgkin lymphoma (NHL) 2. Hodgkin (disease)

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma

Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma Classification Diagnostic Tools and Treatment of Non Hodgkin Lymphoma American Society of Cytopathology 59 th Annual Scientific Meeting 2011 Douglas E. Gladstone, MD Clinical Director IPOP Associate Professor

More information

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Chimeric Antigen Receptor T-cell therapy for CD19+ Maligancies

Chimeric Antigen Receptor T-cell therapy for CD19+ Maligancies Chimeric Antigen Receptor T-cell therapy for CD19+ Maligancies Noelle Frey, MD, MSCE Assistant Professor of Medicine Associate Director, Blood and Marrow Transplantation University of Pennsylvania Medical

More information

CYTOKINE RELEASE SYNDROME

CYTOKINE RELEASE SYNDROME CYTOKINE RELEASE SYNDROME Jenny Lee MSN, ACNP-BC, CNS Nurse Practitioner Department of Hematology and Hematopoietic Cell Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV Click

More information

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Tone Kvåle, Chief Financial Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com

More information

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008 Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small

More information

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146 Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D.

Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D. Understanding Lymphoma from a Lab Perspective Mohamed E. Salama M.D. Medical Director, Hematopathology and Immunoperoxidase Staining ARUP Laboratories Lymphoproliferative Disorders Malignant lymphoma 1.

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Population Outcomes of Primary Mediastinal Large B-cell Lymphoma in the Rituximab Era. Karen Ortiz Cruz, MD

Population Outcomes of Primary Mediastinal Large B-cell Lymphoma in the Rituximab Era. Karen Ortiz Cruz, MD Population Outcomes of Primary Mediastinal Large B-cell Lymphoma in the Rituximab Era Karen Ortiz Cruz, MD Introduction Primary Mediastinal Large B-cell Lymphoma (PMLBCL) - a rare entity corresponding

More information

CIRM Webinar: CAR-T Cell Immunotherapy - Challenges and Opportunities Using Mature or Stem Memory T Cells, March 18th, 2015 Margo R Roberts, Ph.D.

CIRM Webinar: CAR-T Cell Immunotherapy - Challenges and Opportunities Using Mature or Stem Memory T Cells, March 18th, 2015 Margo R Roberts, Ph.D. CIRM Webinar: CAR-T Cell Immunotherapy - Challenges and Opportunities Using Mature or Stem Memory T Cells, March 18th, 2015 Margo R Roberts, Ph.D. Forward Looking Statements / Safe Harbor To the extent

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development

More information

Anti-HCV therapy in HCV-related NHL

Anti-HCV therapy in HCV-related NHL Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral

More information

Chimeric Antigen Receptor Engineered T-Cell Therapy Presenters: Overview and Clinical Management Date:

Chimeric Antigen Receptor Engineered T-Cell Therapy Presenters: Overview and Clinical Management Date: Title: Chimeric Antigen Receptor Engineered T-Cell Therapy Presenters: Overview and Clinical Management Date: L. Elizabeth Budde, MD, PhD Department of Hematology & HCT T cell Therapeutics Research Laboratory

More information

Non Hodgkins Lymphoma primary treatment

Non Hodgkins Lymphoma primary treatment Non Hodgkins Lymphoma primary treatment R-CHOP 21 R-CHOP 14 Primary chemotherapy for diffuse large B cell NHL. Treatment option for: * low-grade NHL with high-grade transformation or high risk features.

More information

The 5 W s of Autologous Transplant for Lymphoma

The 5 W s of Autologous Transplant for Lymphoma The 5 W s of Autologous Transplant for Lymphoma Dr. Kristjan Paulson, BSc, BSc(Med), MSc, MD, FRCPC Assistant Professor, University of Manitoba, Faculty of Medicine Department of Internal Medicine CancerCare

More information

Presenter Disclosure: Renier J. Brentjens, MD, PhD. Nothing to disclose

Presenter Disclosure: Renier J. Brentjens, MD, PhD. Nothing to disclose Presenter Disclosure: Renier J. Brentjens, MD, PhD Nothing to disclose Adoptive Therapy of Cancer with T cells Genetically Targeted to Tumor Associated Antigens through the Introduction of Chimeric Antigen

More information

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection

More information

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 3, September 17, 2015 Engineering the Immune System to Recognize Myeloma Cells Speakers Moderator: David Avigan, MD Harvard

More information

Disease Response. Objectives

Disease Response. Objectives Disease Response Susan Barry, Clinical Trials Manager CALGB Statistical Center CRA Committee: New CRA Session 2010 Summer Group Meeting Objectives Review response criteria for solid tumor cancers, lymphomas,

More information

Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,

More information

Clinical Research Program Information for Patients. Transplant Creations

Clinical Research Program Information for Patients. Transplant Creations Clinical Research Program Information for Patients Transplant Creations 1 Program Focus Combination chemotherapy and transplantation of stem cells from an autologous donor (patient s own stem cells) and/or

More information

Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del

Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del Allogene Neues vom immunologischen Ctrl-Alt-Del Prof. Dr. med. Wolfgang Bethge Allogene am ASH Insgesamt 715 Abstracts zum Thema Auswahl: Azacitidine als Überbrückung zu allogenen SZT bei MDS Ergebnis

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

CAR T Cell Immunotherapy A LIVING DRUG TO FIGHT CANCER

CAR T Cell Immunotherapy A LIVING DRUG TO FIGHT CANCER CAR T Cell Immunotherapy A LIVING DRUG TO FIGHT CANCER One new cancer treatment being studied is CAR T cell (Chimeric Antigen Receptor T cell) therapy. CAR T cell therapy uses a patient s own cells and

More information

New Targets and Treatments for Follicular Lymphoma. Disclosures

New Targets and Treatments for Follicular Lymphoma. Disclosures Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:

More information

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities

More information

Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa

Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com 1

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

The use of monoclonal antibodies in the setting of HSCT

The use of monoclonal antibodies in the setting of HSCT The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

1. Introduction. 2. Clinical aspects

1. Introduction. 2. Clinical aspects 1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

storage and handling of unused stem cell products Swiss consensus?

storage and handling of unused stem cell products Swiss consensus? storage and handling of unused stem cell products Swiss consensus? 16. Jan. 2015 Panagiotis Samaras, Mario Bargetzi stored units USZ Type of unused product autologous stem cells never transplanted 2nd

More information

Lymphomas after organ transplantation

Lymphomas after organ transplantation Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

More information

CLINICAL APPLICATION OF CAR T CELLS

CLINICAL APPLICATION OF CAR T CELLS Memorial Sloan Kettering Cancer Center is pleased to announce CLINICAL APPLICATION OF CAR T CELLS MARCH 10-11, 2016 Conference Location: Memorial Sloan Kettering Cancer Center Zuckerman Research Center

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Cytoreductive Therapy for Autologous Cell Therapy in HIV

Cytoreductive Therapy for Autologous Cell Therapy in HIV Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME II LYMPHOMA CHAPTER 9 REVISED: OCTOBER 2014

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME II LYMPHOMA CHAPTER 9 REVISED: OCTOBER 2014 Disease Information The two main malignant diseases of the lymphoreticular system are non-hodgkin's lymphoma and Hodgkin's disease. Lymphoma is a general term applied to a heterogeneous group of cancers

More information

Stem Cell Transplantation in Leukemia. D. Niederwieser University of Leipzig Germany

Stem Cell Transplantation in Leukemia. D. Niederwieser University of Leipzig Germany Stem Cell Transplantation in Leukemia D. Niederwieser University of Leipzig Germany probability Stem Cell Transplantation in Acute Myeloid Leukemia Outcome according to cytogenetics AML 96 n = 35, 163,

More information

KITE PHARMA, INC. FORM 424B1. (Prospectus filed pursuant to Rule 424(b)(1)) Filed 12/12/14

KITE PHARMA, INC. FORM 424B1. (Prospectus filed pursuant to Rule 424(b)(1)) Filed 12/12/14 KITE PHARMA, INC. FORM 424B1 (Prospectus filed pursuant to Rule 424(b)(1)) Filed 12/12/14 Address 2225 COLORADO AVENUE SANTA MONICA, CA 90404 Telephone (310) 824-9999 CIK 0001510580 Symbol KITE SIC Code

More information

Non-Hodgkin s Lymphoma

Non-Hodgkin s Lymphoma Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant

More information

SEPTEMBER 2015 MICHAEL OREDSSON,CEO

SEPTEMBER 2015 MICHAEL OREDSSON,CEO SEPTEMBER 2015 MICHAEL OREDSSON,CEO 2 INVESTMENT HIGHLIGHTS Combines the valuable n-coder library of 30 billion antibodies with the proprietary F.I.R.S.T technology to identify the right antibodies for

More information

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging

More information

T Cell Immunotherapy for Cancer

T Cell Immunotherapy for Cancer T Cell Immunotherapy for Cancer Chimeric Antigen Receptors Targeting Tag-72 Glycoprotein for Colorectal Cancer Mitchell H. Finer Ph.D Genetix Pharmaceuticals Inc Work Completed at Cell Genesys Inc T Cell

More information

A disease and antibody biology approach to antibody drug discovery

A disease and antibody biology approach to antibody drug discovery A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Innovating antibodies, improving lives

Innovating antibodies, improving lives ANNUAL REPORT 2014 Innovating antibodies, improving lives Genmab A/S CVR No. 21 02 38 84 DIRECTORS REPORT TABLE OF CONTENTS PRODUCTS Table of Contents Directors Report page 1 Genmab At-A-Glance 1 Shareholder

More information

Audience Response Question?

Audience Response Question? Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships

More information

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH AN INTRODUCTION TO THE LYMPHOPROLIFERATIVE DISORDERS BY DR Y PERNER DEPARTMENT OF ANATOMICAL PATHOLOGY OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib

More information

information for payers and referrers

information for payers and referrers a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in

More information

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data (Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at

More information

Cowen and Company 35 th Annual Healthcare Conference

Cowen and Company 35 th Annual Healthcare Conference Personalized Therapeutics The Power of Epigenetics Cowen and Company 35 th Annual Healthcare Conference March 2015 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking

More information

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Petitioner, v. Biogen Idec, Inc.

More information

Advancing Therapies for Blood Cancers

Advancing Therapies for Blood Cancers Advancing Therapies for Blood Cancers Stuart L. Goldberg, MD Chief, Division of Leukemia John Theurer Cancer Center Hackensack University Medical Center Hackensack, NJ Associate Clinical Professor of Medicine

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

Lymphoma Reporting Basics

Lymphoma Reporting Basics Disclosures Lymphoma Reporting Basics January 31, 212 Janet Brunner, PA-C I have nothing to disclose P. Hari, MD MS I have nothing to disclose G. Laport, MD I have nothing to disclose New1_1.ppt Objectives

More information

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not

More information

Strategies for personalized cell therapy Lessons from CAR T Cells

Strategies for personalized cell therapy Lessons from CAR T Cells Strategies for personalized cell therapy Lessons from CAR T Cells David L Porter, MD Jodi Fisher Horowitz Professor, Director Blood and Marrow Transplantation University of Pennsylvania Health System Abramson

More information

What to do with bad PBSC mobilizers?

What to do with bad PBSC mobilizers? What to do with bad PBSC mobilizers? Rafael F. Duarte Director Programa de Trasplante Jefe Sección de Onco-Hematología Are poor mobilizers a real problem? Plerixafor, Mozobil Product characteristics Efficacy

More information

Specimen Collection HEMATOLOGICAL MALIGNANCIES. CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ SOLID TUMORS

Specimen Collection HEMATOLOGICAL MALIGNANCIES. CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ SOLID TUMORS Specimen Collection Specimen Retrieval Kits 2 Sending your Specimens 2 Labeling Instructions 2 Handling of a Bone Marrow Specimen Dry Tap 3 CGI LABORATORIES 201 Route 17 North, 2nd Floor Rutherford, NJ

More information

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma This appendix is intended to provide additional information on: Common pre-hct treatments for lymphoma, Lines of therapy, Cycles, and How to report

More information

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05- Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

Novità dall EHA >> [ Leucemia linfatica cronica ]

Novità dall EHA >> [ Leucemia linfatica cronica ] Novità dall EHA >> [ Leucemia linfatica cronica ] Relatore: P. GHIA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia linfatica cronica - Copyright FSE 1 Number and type of abstracts 2 Number

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous

More information

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies Saar Gill Carl H. June Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies Authors addresses Saar Gill 1, Carl H. June 2 1 Abramson Cancer Center, Division of Hematology/

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

#EBMTLymphoma

#EBMTLymphoma 11th Educational Course of the EBMT Lymphoma Working Party on "Treatment of Malignant Lymphoma: State-of-the-Art and Role of Stem Cell Transplantation Heidelberg (Germany), September 24-26, 2015 #EBMTLymphoma

More information

HKU Identifies Homoharringtonine as Effective Treatment for FLT3 Mutant Acute Myeloid Leukaemia for the First Time in the World

HKU Identifies Homoharringtonine as Effective Treatment for FLT3 Mutant Acute Myeloid Leukaemia for the First Time in the World HKU Identifies Homoharringtonine as Effective Treatment for FLT3 Mutant Acute Myeloid Leukaemia for the First Time in the World Press Conference October 31, 2016 Speakers Professor Anskar Leung Yu-hung

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information